-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE : To elucidate the mechanism of action of baricitinib , a Janus kinase (JAK) 1/2 inhibitor , and to describe disease activity-related disease activity in adult patients with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II tri.
OBJECTIVE: To elucidate the mechanism of action of baricitinib , a Janus kinase (JAK) 1/2 inhibitor , and to characterize disease activity-related immunity in adult patients with systemic lupus erythematosus (SLE) receiving standard background therapy in a phase II tri.
Methods : In a phase II randomized, placebo-controlled study, patients with SLE received either 2mg or 4 mg of baricitini.
Methods In a phase II randomized, placebo-controlled study, patients with SLE received either 2 mg or 4 mg of baricitini.
Results At baseline, SLE sera had marked cytokine dysregulation relative to HC ser.
Conclusions: These results suggest that baricitinib 4 mg downregulates key cytokines that are upregulated in SLE patients and may play a role in a multi-target mechanism beyond the IFN signature, although the clinical relevance remains to be further describe.
Dörner T, Tanaka Y, Dow ER , et a.
Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematos.
Annals of the Rheumatic DiseasesPublished Online First: 24 May 202 doi: 11136/ annrheumdis-2022-222335 , et al Annals of the Rheumatic Diseasesleave a comment here